Feature | Left Atrial Appendage (LAA) Occluders | September 27, 2021

FDA Concerned About Higher Rates of LAA Occlusion Complications in Women

FDA issues letter to providers on possible safety issues with left atrial appendage occlusion in women compared to men

Illustration of the Watchman transcatheter left atrial appendage (LAA) occluder being  deployed into the LAA. FDA is concerned about higher rates of LAA occlusion complications in women compared to men, prompting the FDA to send a letter to providers warning them on possible poor outcomes.

Illustration of the Watchman transcatheter left atrial appendage (LAA) occluder being  deployed into the LAA. 


September 27, 2021 — Compared with men undergoing left atrial appendage occlusion (LAAO), women have a significantly higher risk of in-hospital adverse events, according to a recently published review of more than 49,000 patients in the National Cardiovascular Data Registry LAAO Registry.[1] This data prompted the U.S. Food and Drug Administration (FDA) today to issue a safety letter to providers outlining the potential safety issues in women.

The FDA letter sent Sept. 27, informs healthcare providers of recent information about the potential for differences in procedural outcomes between women and men undergoing implant of a left atrial appendage occlusion device. The agency said it is evaluating a study published in August in the Journal of the American Medical Association (JAMA) Cardiology.[1] This analysis of real-world data in the National Cardiovascular Data Registry LAAO Registry from 49,357 patients undergoing LAAO procedures with the Watchman Left Atrial Appendage Closure device from 2016 to 2019 indicates that procedural outcomes, such as major adverse events and lengthened hospital stay, may be more common in women compared to men. 

The causes for these differences are yet to be determined, the FDA said. The agency said it will work with the manufacturers of approved LAAO devices to evaluate information from several sources, including premarket studies, mandated post-market studies, and real-world data to provide additional information on this issue. 

Despite the study raising a red flag, the FDA said it believes the benefits continue to outweigh the risks for approved LAAO devices when used in accordance with their instructions for use.

FDA Recommendations for Healthcare Providers on LAA Occlusion:

The FDA recommends that healthcare providers:
   • Continue monitoring patients who have been treated with LAAO devices per the current standard of care.
   • Discuss the risks and benefits of all available options for stroke prevention in patients with atrial fibrillation as part of shared clinical decision-making.
   • Report any adverse events or suspected adverse events experienced with the use of LAAO devices. Voluntary reports can be submitted through MedWatch, the FDA Safety Information and Adverse Event Reporting program. Device manufacturers and user facilities must comply with the applicable Medical Device Reporting (MDR) regulations. Healthcare personnel employed by facilities that are subject to FDA's user facility reporting requirements should follow the reporting procedures established by their facilities. Prompt reporting of adverse events can help the FDA identify and better understand the risks associated with medical devices.

FDA Will Be Watching Data on Two Transcatheter LAA Occluders

LAAO devices are implanted in the heart and are intended to reduce the risk of thromboembolism from the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation. The device mechanically occludes the LAA to prevent LAA thrombus from entering the systemic circulation. The manufacturers of the currently approved and marketed LAAO devices in the U.S. are Abbott Amplatzer Amulet device and Boston Scientific Watchman and Watchman FLX devices.

Study Showing Safety Concern in LAAO Registry Data

The recent article by Darden et al. presented an analysis of 49,357 patients from the LAAO registry (41.3% women and 58.7% men) treated with the Watchman device between 2016 to 2019. The authors found a statistically significant higher rate of adverse procedural events in women compared to men including any adverse events (6.3% vs. 3.9%, p<0.001), any major adverse events (4.1% vs 2%, p<0.001), and hospital stay longer than one day (16% vs 11.6%, p<0.001). 

Among specific procedural adverse events, the rates of pericardial effusion requiring percutaneous drainage was 1.2% vs. 0.5% and major bleeding was 1.7% vs. 0.8% in women vs. men, respectively. Procedure-associated death was 0.3% in women and 0.1% in men.

The FDA said it recognizes the limitations of these data, including that the study was not randomized, only included one LAAO device (the first-generation Watchman device), and did not include longer-term outcomes beyond in-hospital events. However, the analysis provides results from a large registry of patients treated with LAAO implants in the U.S.

Registries are real-world databases that can be used to track how patients respond to particular medical devices and are one source the FDA uses to monitor post-market device safety and effectiveness. Because the National Cardiovascular Data Registry LAAO Registry captures a large number of patients undergoing LAAO procedures, the number of patients included in this analysis was much larger than the number of patients that were included in the premarket studies of the Watchman device that supported device approval, and the premarket studies for the other approved LAAO devices. 

FDA Working With LAA Occluder Vendors to Gather More Safety Data

The FDA said it is working with the manufacturers to evaluate the potential issue of sex differences in procedural outcomes with LAAO devices, including a review of available premarket and post-approval study data, and other available real-world post-market data sets. In addition, the FDA will work with the device manufacturers, investigators, and the LAAO Registry to try to identify the causes of procedural outcome differences between women and men.

The FDA said it will communicate with the public if new or additional information becomes available.

 

Related LAA Occluder Content:

FDA Clears Abbott Amplatzer Amulet LAA Occluder to Reduce Stroke in People With Atrial Fibrillation

VIDEO: Overview of LAA Occlusion Using the Watchman FLX — Interview with Devi G. Nair, M.D.

NCDR LAAO Registry Shows Left Atrial Appendage Occlusion Associated With Low Rate of Stroke

Occluding the Left Atrial Appendage (LAA)

VIDEO: Comparison Between Watchman vs. Amulet LAA Occluders — Interview with Ashish Pershad, M.D.

 

First-Of-Its-Kind, No-Implant LAA Occluder Noted for Innovation at 2019 ICI Meeting

VIDEO: Overview of Left Atrial Appendage (LAA) Closure Technology and New Innovations — Interview with Horst Sievert, M.D.

Amplatzer Amulet LAA Occluder Will be Compared to Anticoagulants in CATALYST Trial

VIDEO: Gender Differences in Diagnosing Heart Disease in Women — Interview with Doreen DeFaria Yeh, M.D.

Find more new on Left Atrial Appendage (LAA) Occluders

Reference:

1. Darden, Douglas et al. Sex Differences in Procedural Outcomes Among Patients Undergoing Left Atrial Appendage Occlusion. JAMA Cardiol 2021 Aug 11; e213021. DOI: 10.1001/jamacardio.2021.3021, Online ahead of print.

Related Content

News | Atrial Fibrillation

September 28, 2021 — Image-guided fibrosis ablation in addition to pulmonary vein isolation (PVI) does not improve ...

Home September 28, 2021
Home
News | Atrial Fibrillation

September 13, 2021 — Ablation plus cardiac resynchronization therapy (CRT) is superior to pharmacological rate control ...

Home September 13, 2021
Home
News | Atrial Fibrillation

September 8, 2021 — Continuous heart rhythm monitoring – with anticoagulation if atrial fibrillation is detected – does ...

Home September 08, 2021
Home
News | Atrial Fibrillation

August 9, 2021 — Adagio Medical Inc., a provider of catheter ablation technologies for atrial fibrillation (AF) and ...

Home August 09, 2021
Home
News | Atrial Fibrillation

June 23, 2021 — The U.S. Food and Drug Administration (FDA) expanded approval for Medtronic's Arctic Front Family of ...

Home June 23, 2021
Home
News | Atrial Fibrillation

April 19, 2021 — National Heart, Lung, and Blood Institute (NHLBI) has awarded a grant for $462,689 to Rhythm ...

Home April 19, 2021
Home
News | Atrial Fibrillation

March 3, 2021 — Farapulse Inc. announced the first patients were treated in the ADVENT Trial, a U.S. Food and Drug ...

Home March 03, 2021
Home
News | Atrial Fibrillation

January 29, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Medtronic's DiamondTemp Ablation (DTA) system ...

Home January 29, 2021
Home
Feature | Atrial Fibrillation | By John D. Day, M.D., T. Jared Bunch, M.D., and Matthew D. LaPlante

In our most challenging and distressing days, it is nice to think about a post-COVID-19 world. But while this pandemic ...

Home January 27, 2021
Home
News | Atrial Fibrillation

December 23, 2020 — The American College of Cardiology (ACC) and the American Heart Association (AHA) has made two ...

Home December 23, 2020
Home
Subscribe Now